BIO: Biotech Funding Captured By Oncology
This article was originally published in The Pink Sheet Daily
A report released May 19 from the industry organization confirms that oncology is attracting the most funding, while some other surprising therapeutics areas have become of interest to investors.
You may also be interested in...
Overview of venture capital investment in the life sciences last year shows that overall investment in biotech rose, rounds were larger, and investment in Series A rounds increased, as well.
Big pharma keeps marching into immuno-oncology, and partnering in the field has been one of the biggest deal drivers of 2015. It’s not yet a big factor in M&A, which this year has been driven by payer pressure and generics consolidation.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.